BioWorld

Jan. 21, 2003

Amgen Hits Endpoints In First Enbrel Psoriasis Phase III Trial

The first of two Enbrel Phase III trials in psoriasis hit its primary and secondary endpoints, pushing Amgen Inc. to the halfway point in its quest to grow the blockbuster drug through the addition of another large market. (BioWorld Today) Read More

NPS's Phase III Bone Treatment Tested In Shuttle's Microgravity

FDA's Authority Over Cloning Questioned At Council Meeting

Holiday Notice

BioWorld's offices were closed Monday in observance of the Martin Luther King Jr. holiday in the U.S. No issue was published that day. Read More

Amylin Sells 9.2M Shares, Raises $152.7M For Symlin

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.